Chicago Equity Partners LLC increased its stake in shares of Steris PLC (NYSE:STE) by 124.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 23,045 shares of the medical equipment provider’s stock after acquiring an additional 12,775 shares during the period. Chicago Equity Partners LLC’s holdings in Steris were worth $2,462,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Rehmann Capital Advisory Group increased its position in Steris by 15.6% during the third quarter. Rehmann Capital Advisory Group now owns 712 shares of the medical equipment provider’s stock worth $81,000 after buying an additional 96 shares during the last quarter. Steward Partners Investment Advisory LLC increased its position in Steris by 118.0% during the third quarter. Steward Partners Investment Advisory LLC now owns 909 shares of the medical equipment provider’s stock worth $104,000 after buying an additional 492 shares during the last quarter. First Hawaiian Bank acquired a new position in Steris during the third quarter worth approximately $106,000. Bartlett & Co. LLC increased its position in Steris by 76.4% during the fourth quarter. Bartlett & Co. LLC now owns 1,235 shares of the medical equipment provider’s stock worth $132,000 after buying an additional 535 shares during the last quarter. Finally, Parallel Advisors LLC increased its position in Steris by 480.4% during the third quarter. Parallel Advisors LLC now owns 1,364 shares of the medical equipment provider’s stock worth $156,000 after buying an additional 1,129 shares during the last quarter. Institutional investors and hedge funds own 91.81% of the company’s stock.
In other news, VP John Adam Zangerle sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, January 25th. The stock was sold at an average price of $115.00, for a total value of $345,000.00. Following the transaction, the vice president now owns 33,796 shares of the company’s stock, valued at $3,886,540. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 2.38% of the stock is currently owned by corporate insiders.
Steris stock opened at $120.19 on Thursday. Steris PLC has a 12 month low of $85.40 and a 12 month high of $123.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.01 and a current ratio of 2.63. The company has a market capitalization of $10.03 billion, a PE ratio of 28.96 and a beta of 1.04.
Steris (NYSE:STE) last posted its earnings results on Monday, February 11th. The medical equipment provider reported $1.26 EPS for the quarter, meeting the consensus estimate of $1.26. Steris had a return on equity of 12.15% and a net margin of 11.72%. The company had revenue of $696.24 million for the quarter, compared to the consensus estimate of $687.90 million. On average, analysts anticipate that Steris PLC will post 4.78 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 21st. Stockholders of record on Wednesday, February 27th will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 1.13%. The ex-dividend date is Tuesday, February 26th. Steris’s payout ratio is 32.77%.
A number of equities analysts have weighed in on STE shares. Sidoti boosted their price target on Steris from $155.00 to $157.00 and gave the stock a “buy” rating in a research report on Thursday, December 6th. Zacks Investment Research reissued a “buy” rating and set a $132.00 price target on shares of Steris in a research report on Friday, November 16th. Finally, KeyCorp boosted their price target on Steris from $120.00 to $132.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 13th. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $134.20.
Steris Company Profile
STERIS plc provides infection prevention and other procedural products and services worldwide. The company operates in four segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products segment offers cleaning chemistries and sterility assurance products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operations of a sterile processing department; and equipment used in the operating room, including surgical tables, lights, equipment management services, and connectivity solutions.
Featured Article: Momentum Investing
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.